晚期肝细胞癌的治疗，重点在于肝动脉灌注化疗和分子靶向治疗。
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2012 Sep;1(2):62-70. doi: 10.1159/000342402.
Abstract
Advanced hepatocellular carcinoma is defined as liver cancer with vascular invasion or extrahepatic metastasis that is untreatable by local therapy. In Japan, hepatic arterial infusion chemotherapy (HAIC) with interferon plus 5-fluorouracil (5-FU) or a combination of low-dose 5-FU and cisplatin, referred to as low-dose FP, is administered for treating advanced liver cancer and yields favorable outcomes. Outside Japan, the molecular targeted agent, sorafenib, is used as a first-line treatment for advanced liver cancer. New drug development for advanced liver cancer and clinical trials on combination therapy with sorafenib and HAIC are currently underway. The prognosis of advanced liver cancer will significantly improve if these clinical trials yield positive results.
摘要
晚期肝细胞癌被定义为伴有血管侵犯或肝外转移且无法通过局部治疗治愈的肝癌。在日本，采用干扰素联合5-氟尿嘧啶（5-FU）或低剂量5-FU与顺铂联合（即低剂量FP方案）的肝动脉灌注化疗（HAIC）用于治疗晚期肝癌，并取得了良好疗效。在日本以外地区，分子靶向药物索拉非尼被用作晚期肝癌的一线治疗药物。目前正在进行晚期肝癌的新药研发以及索拉非尼与HAIC联合治疗的临床试验。如果这些临床试验取得阳性结果，晚期肝癌的预后将得到显著改善。
相似文献
1
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
Liver Cancer. 2012 Sep;1(2):62-70. doi: 10.1159/000342402.
2
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
3
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
4
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Clin Drug Investig. 2012 Aug 8;32 Suppl 2:15-23. doi: 10.1007/BF03265493.
5
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy.
World J Hepatol. 2018 Sep 27;10(9):571-584. doi: 10.4254/wjh.v10.i9.571.
6
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
7
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24.
8
Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.
Mol Clin Oncol. 2017 Dec;7(6):1013-1020. doi: 10.3892/mco.2017.1442. Epub 2017 Oct 4.
9
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
J Cancer Res Clin Oncol. 2021 Oct;147(10):3123-3133. doi: 10.1007/s00432-021-03632-4. Epub 2021 Apr 23.
10
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
PLoS One. 2019 Jun 13;14(6):e0218136. doi: 10.1371/journal.pone.0218136. eCollection 2019.
引用本文的文献
1
Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma.
Discov Oncol. 2025 Jun 13;16(1):1081. doi: 10.1007/s12672-025-02914-4.
2
The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.
Curr Oncol. 2025 Feb 4;32(2):87. doi: 10.3390/curroncol32020087.
3
Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma.
World J Gastrointest Oncol. 2024 Dec 15;16(12):4766-4769. doi: 10.4251/wjgo.v16.i12.4766.
4
Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma.
Am J Cancer Res. 2024 Oct 15;14(10):4922-4934. doi: 10.62347/HVOF5644. eCollection 2024.
5
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Front Immunol. 2024 May 10;15:1397827. doi: 10.3389/fimmu.2024.1397827. eCollection 2024.
6
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
Front Immunol. 2023 Oct 31;14:1284937. doi: 10.3389/fimmu.2023.1284937. eCollection 2023.
7
NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
Cancer Sci. 2024 Feb;115(2):465-476. doi: 10.1111/cas.16029. Epub 2023 Nov 22.
8
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.
Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21.
9
Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.
BMC Complement Med Ther. 2023 Sep 19;23(1):329. doi: 10.1186/s12906-023-04142-1.
10
Involvement and targeted intervention of benzo(a)pyrene-regulated apoptosis related proteome modification and muti-drug resistance in hepatocellular carcinoma.
Cell Death Dis. 2023 Apr 12;14(4):265. doi: 10.1038/s41419-023-05771-7.
本文引用的文献
1
Report of the 18th follow-up survey of primary liver cancer in Japan.
Hepatol Res. 2010 Nov;40(11):1043-1059. doi: 10.1111/j.1872-034X.2010.00731.x.
2
Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging.
Liver Cancer. 2012 Jun;1(1):51-8. doi: 10.1159/000339020.
3
Chemoembolization in patients with hepatocellular carcinoma.
Liver Cancer. 2012 Jun;1(1):41-50. doi: 10.1159/000339019.
4
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.
Dig Dis. 2011;29(3):339-64. doi: 10.1159/000327577. Epub 2011 Aug 9.
5
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
Dig Dis. 2011;29(3):321-5. doi: 10.1159/000327570. Epub 2011 Aug 9.
6
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.
7
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
8
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Oncology. 2010 Jul;78 Suppl 1:148-53. doi: 10.1159/000315244. Epub 2010 Jul 8.
9
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
10
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件